Quarterly Result30 May 2026, 08:41 pm
Vanta Bioscience: FY26 Audited Results Approved
AI Summary
Vanta Bioscience Ltd's Board of Directors approved the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. Mr. Dopesh Raja Mulakala has been re-appointed as Managing Director for another 3 years effective April 18, 2026, subject to shareholder approval. The statutory auditors, M/s Mathesh & Ramana, issued an unmodified opinion on the financial results. For FY26, Vanta Bioscience reported total revenue of ₹167.41 Lacs and a net profit of ₹1.81 Lacs.
Key Highlights
- Audited FY26 standalone and consolidated financial results approved.
- Dopesh Raja Mulakala re-appointed as Managing Director for 3 years.
- Auditors issued an unmodified opinion on FY26 financial results.
- FY26 total revenue reported at ₹167.41 Lacs.
- FY26 net profit reported at ₹1.81 Lacs.
Price Impact
More from VANTABIO